结核病免疫治疗年度进展2023  

Annual progress of immunotherapy for tuberculosis in 2023

作　　者：柯荟 范琳[1] Ke Hui;Fan Lin(Department of Tuberculosis,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai Clinic and Research Center of Tuberculosis,Shanghai Key Laboratory of Tuberculosis,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院结核科,上海市感染性疾病(结核病)医学临床研究中心,上海市结核(肺)重点实验室,上海200433

出　　处：《中华结核和呼吸杂志》2024年第4期371-375,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家自然科学基金(82170006)。

摘　　要：结核病作为一种慢性感染性疾病,与免疫调控及免疫效应密切相关。免疫治疗作为结核病综合治疗的重要手段之一,可改善结核病的疗效、控制结核病的传播。2022年10月至2023年9月,国内外进行了多项关于结核病的免疫治疗研究,对耐多药、广泛耐药结核的治疗提供了新的可能。宿主靶向治疗及治疗性疫苗的研究是结核病辅助治疗探索的新方向。As a chronic infectious disease,tuberculosis(TB)is closely related to immune regulation and immune effect.Immunotherapy which can improve the curative effect of tuberculosis and control the spread of tuberculosis,is one of the important means for the comprehensive treatment of tuberculosis.From October 2022 to September 2023,research on the immunotherapy of tuberculosis at home and abroad continues to increase,providing new opportunities for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.Host-targeted therapy and therapeutic vaccines are new directions for research into TB adjuvant therapy.

关 键 词：慢性感染性疾病 免疫治疗 广泛耐药结核 治疗性疫苗 耐多药 结核病 靶向治疗 免疫调控 

分 类 号：R52[医药卫生—内科学]